Aberrant signaling pathways such as mTOR or pro-tumoral functions such as VEGF release have been individually targeted in GBM therapy, using rapamycin (or its derivatives) or bevacizumab, respectively, but have shown a limited influence on overall survival of GBM patients to date [20,21]. This evidence concerns the gene VEGFA and glioblastoma.